Assenagon Asset Management S.A. Trims Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Assenagon Asset Management S.A. lowered its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 16.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 323,376 shares of the company’s stock after selling 62,044 shares during the period. Assenagon Asset Management S.A. owned 0.08% of GoodRx worth $1,504,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in GDRX. Fortem Financial Group LLC purchased a new stake in GoodRx in the 3rd quarter valued at about $772,000. Barclays PLC raised its stake in GoodRx by 1,316.1% during the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after purchasing an additional 130,219 shares during the period. Charles Schwab Investment Management Inc. raised its stake in GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after purchasing an additional 26,262 shares during the period. Raymond James & Associates boosted its holdings in shares of GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock valued at $2,734,000 after purchasing an additional 267,951 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its position in shares of GoodRx by 260.7% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock worth $308,000 after buying an additional 32,104 shares during the period. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Trading Up 4.7 %

Shares of NASDAQ GDRX opened at $4.93 on Friday. The stock has a market capitalization of $1.88 billion, a P/E ratio of -164.33, a PEG ratio of 2.38 and a beta of 1.27. The stock’s 50 day moving average price is $4.59 and its two-hundred day moving average price is $6.37. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 52-week low of $4.09 and a 52-week high of $9.26.

Wall Street Analysts Forecast Growth

GDRX has been the subject of a number of research reports. Mizuho began coverage on GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price target for the company. Morgan Stanley lowered their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Citigroup dropped their price objective on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Barclays dropped their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, KeyCorp decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Five equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GoodRx has a consensus rating of “Moderate Buy” and a consensus price target of $8.38.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.